Abstract
Medicine repurposing is a strategy to identify new uses for existing medicines for the purpose of addressing areas of unmet medical need. This paper aims to provide horizon scanning intelligence on repurposed medicines that are evaluated by non-commercial organisations such as academia, and highlights opportunities for further research to improve patient health outcomes. A scan of the clinical landscape of non-commercially sponsored repurposed medicines is routinely conducted by the NIHR Innovation Observatory (IO). This ongoing project involves a horizon scan of clinical trial registries and the internal horizon scanning Medicines Innovation Database (MInD) of the NIHR IO to identify potential candidate medicines used as monotherapy or in combination to treat new indications outside the scope of their licensed indication. In addition to making these data publicly available, the output also supports the NHS England Medicines Repurposing Programme (MRP). The snapshot scan reported here (trials completing April 2020 to March 2023) identified a total of 528 technologies (meaning, a single product or combination of medicinal products targeting a specific indication in one or more related trials). The technologies were classified according to their characteristics and targeted therapeutic indications as well as revealing the least treated disease conditions. The candidate medicines identified in this scan could potentially receive tailored support towards adoption into practice and policy. The NIHR IO regularly provides this scan as a source of intelligence on repurposed medicines. This provides valuable insights into innovation trends, gaps, and areas of unmet clinical need.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is funded by the NIHR (HSRIC-2016-10009)/Innovation Observatory]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses of co-authors: Ross Fairbairn ross.fairbairn{at}ncl.ac.uk, Alex Inskip alex.inskip{at}ncl.ac.uk, Rhiannon Potter rhiannon.potter{at}ncl.ac.uk, Aoife Oliver aoife.oliver{at}ncl.ac.uk, Dawn Craig dawn.craig{at}ncl.ac.uk
Data Availability
All data produced in the present work are contained in the manuscript, and on the Repurposed medicines dashboard on the NIHR Innovation Observatory website https://www.io.nihr.ac.uk/dashboardpages/repurposed-medicines-dashboard/
https://www.io.nihr.ac.uk/dashboardpages/repurposed-medicines-dashboard/
